Company Encyclopedia
View More
name
Direxion Daily LLY Bull 2X Shares
ELIL.US
News
View More

Key facts: Eli Lilly to Cut Weight-Loss Drug Prices; Study Shows Spending Drop

Eli Lilly will cut US prices for its weight-loss drugs to $149 monthly for the lowest doses, coinciding with anticipated Medicare coverage expansion next year, reducing patient costs.1A Cornell study found households using Eli Lilly's Zepbound cut grocery spending by 5.3% in six months, with higher-income households reducing spending by 8.2%, especially on snacks.2

TradingView·
US
LLY
+0.07%
TradingView·
US
LLY
+0.07%

Best Pharmaceutical Stocks To Follow Now - December 26th

MarketBeat's stock screener tool highlights Eli Lilly, Novo Nordisk, and Pfizer as pharmaceutical stocks to watch. These stocks are influenced by clinical trials, regulatory approvals, and drug-pricing dynamics, making them volatile. Eli Lilly, Novo Nordisk, and Pfizer have high trading volumes recently. MarketBeat suggests Eli Lilly has a Moderate Buy rating, but top analysts recommend other stocks as better buys.

Market Beat·
US
LLY
+0.07%
US
NVO
-0.30%
Market Beat·
US
LLY
+0.07%
US
NVO
-0.30%

Mixed sector performances as tech and healthcare show gains

The US stock market shows mixed sector performances, with technology and healthcare sectors gaining. NVDA leads tech gains at 0.68%, while LLY posts a 0.19% increase in healthcare. Semiconductors show mixed results, and financials remain stable. Communication services are lukewarm. Investors are advised to increase positions in tech and semiconductors, monitor healthcare trends, and adjust exposure in financial stocks. Visit InvestingLive.com for more insights.

Investinglive·
US
LLY
+0.07%
Investinglive·
US
LLY
+0.07%

Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access

Eli Lilly and Novo Nordisk are cutting GLP-1 drug prices as oral pill approvals expand access. Lilly's Zepbound shows stronger weight-loss outcomes than Novo's Wegovy. Novo's oral GLP-1 pill, expected to be cheaper, broadens access. Both companies are expanding into adjacent conditions, enhancing long-term investment prospects. Pricing and access are central, with agreed price cuts and expanded Medicare coverage. Competition in the GLP-1 market is set to intensify with new entrants like Pfizer.

GuruFocus·
US
NVO
-0.30%
US
LLY
+0.07%
GuruFocus·
US
NVO
-0.30%
US
LLY
+0.07%

Eli Lilly Makes License Deal Payment, Equity Investment in South Korean Biotech ABL Bio

Eli Lilly Makes License Deal Payment, Equity Investment in South Korean Biotech ABL Bio

marketscreener·
US
LLY
+0.07%
marketscreener·
US
LLY
+0.07%
© 2025 Longbridge｜Disclaimer